Organon (OGN) Income from Continuing Operations (2020 - 2026)
Organon (OGN) posted quarterly Income from Continuing Operations of 146000000.0 for Q1 2026, up 67.82% year-over-year from 87000000.0 in Q1 2025, and up 171.22% on a QoQ basis from 205000000.0 in Q4 2025.
Organon (OGN) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Income from Continuing Operations for 7 consecutive years, with 146000000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 67.82% year-over-year to 146000000.0; the TTM figure through Mar 2026 stood at 246000000.0 (down 67.2% YoY), while the FY2025 annual figure was 187000000.0, down 78.36% from the prior year.
- Income from Continuing Operations came in at 146000000.0 for Q1 2026 at Organon, up from 205000000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 546000000.0 in Q4 2023, with the low at 205000000.0 in Q4 2025.
- Average Income from Continuing Operations over 5 years is 210000000.0, with a median of 195000000.0 recorded in 2024.
- Across the five-year window, Income from Continuing Operations jumped 518.97% in 2024 and slumped 288.07% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 541000000.0 in 2022, then grew by 0.92% to 546000000.0 in 2023, then sank by 80.04% to 109000000.0 in 2024, then plunged by 288.07% to 205000000.0 in 2025, then jumped by 171.22% to 146000000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 146000000.0, 205000000.0, and 160000000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.40 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 5.24 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 697.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 833.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 146.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.00 Mn |
| Dec 31, 2025 | -205.00 Mn |
| Sep 30, 2025 | 160.00 Mn |
| Jun 30, 2025 | 145.00 Mn |
| Mar 31, 2025 | 87.00 Mn |
| Dec 31, 2024 | 109.00 Mn |
| Sep 30, 2024 | 359.00 Mn |
| Jun 30, 2024 | 195.00 Mn |
| Mar 31, 2024 | 201.00 Mn |
| Dec 31, 2023 | 546.00 Mn |
| Sep 30, 2023 | 58.00 Mn |
| Jun 30, 2023 | 242.00 Mn |
| Mar 31, 2023 | 177.00 Mn |
| Dec 31, 2022 | 541.00 Mn |
| Sep 30, 2022 | 227.00 Mn |
| Jun 30, 2022 | 234.00 Mn |
| Mar 31, 2022 | 348.00 Mn |
| Dec 31, 2021 | 202.00 Mn |
| Sep 30, 2021 | 323.00 Mn |
| Jun 30, 2021 | 431.00 Mn |